Global BCG Vaccine Sales Market Size By Type of BCG Vaccine, By Application, By Distribution Channel, By Geographic Scope And Forecast

<p>BCG Vaccine Sales Market size was valued at USD 149.67 Million in 2023 and is projected to reach USD 229.09 Million by 2030, growing at a CAGR of 6.27% during the forecast period 2024-2030.</p>
<p>Global BCG Vaccine Sales Market Drivers</p>
<p>The market drivers for the BCG Vaccine Sales Market can be influenced by various factors. These may include:</p>
<p>Worldwide Initiatives to Fight Tuberculosis (TB): The main application of Bacillus Calmette-Guérin (BCG) is in the prevention of tuberculosis. The market for BCG vaccinations is driven by initiatives taken by governments, non-governmental organizations, and global health organizations to reduce the incidence of tuberculosis (TB), particularly in high-burden areas.<br />
Government Immunisation Programmes: The BCG vaccine is a common component of national immunization programmes in many nations, particularly for infants. The consistent demand for BCG vaccines is fueled by government measures to stop the spread of tuberculosis.<br />
Expanding Into Emerging Markets: The BCG vaccine is extensively utilised in both emerging and developed markets. BCG vaccinations will likely become more accessible and affordable as emerging economies’ healthcare infrastructure develops, which will fuel market expansion.<br />
Public health preparedness: Fears about the safety of the world’s health and the readiness for any outbreaks, such as infectious diseases like tuberculosis, push governments and medical associations to keep enough vaccine supplies on hand to enable the sale of the BCG vaccine.<br />
Research & Development Initiatives: Continual efforts to enhance currently available vaccines, such as BCG, and investigate their possible uses outside of tuberculosis prevention can spur new product development and market expansion.<br />
Greater Recognition of the Value of vaccinations: As people and communities grow more pro-active in their healthcare, there is a greater demand for vaccinations, such as BCG, as a result of public awareness campaigns highlighting the value of immunization and disease prevention.<br />
High TB Incidence in Certain Areas: BCG vaccines are consistently required in areas where tuberculosis is highly prevalent. Sales of BCG vaccines are still significantly influenced by the prevalence of TB, particularly in nations where TB is endemic.<br />
International Collaboration in Healthcare: The market for the BCG vaccination may benefit from cooperative efforts among governments, pharmaceutical firms, and international organizations to solve global health issues, such as tuberculosis.<br />
Travel and Migration Patterns: People may relocate between areas with varying TB prevalence rates, which can have an impact on vaccination policies and practices. This might lead to an increase in the demand for BCG vaccinations.<br />
Worldwide Pandemic Readiness: The significance of being ready for infectious illnesses has been highlighted by the COVID-19 pandemic. The market for BCG vaccines could gain from increasing attention to and funding for immunization programs as a result of this focus on global health security.</p>

2023年卡介苗（Bacillus Calmette-Guérin, BCG）销售市场规模达1.4967亿美元，预计至2030年将增至2.2909亿美元，2024-2030年预测期内复合年增长率（Compound Annual Growth Rate, CAGR）为6.27%。
全球卡介苗销售市场驱动因素
卡介苗销售市场的驱动因素受多重因素影响，具体包括：
1. 全球抗击结核病（Tuberculosis, TB）行动：卡介苗的核心应用场景为结核病预防。各国政府、非政府组织及全球卫生机构为降低结核病发病率（尤其是高负担地区）所推行的各类举措，将推动卡介苗疫苗市场增长。
2. 政府免疫规划：卡介苗是多国国家免疫规划的常规组分，尤其针对新生儿群体。政府为遏制结核病传播所采取的相关政策，持续拉动卡介苗疫苗的稳定需求。
3. 新兴市场拓展：卡介苗在新兴与成熟市场均得到广泛应用。随着新兴经济体医疗基础设施不断完善，卡介苗疫苗的可及性与可负担性有望进一步提升，从而驱动市场扩张。
4. 公共卫生应急储备：全球公共卫生安全焦虑以及对各类传染病（如结核病）暴发的防控需求，促使各国政府与医疗协会储备充足的疫苗产品，进而支撑卡介苗疫苗的销售。
5. 研发创新举措：针对卡介苗等现有疫苗的持续优化研究，以及对其在结核病预防以外领域的潜在应用探索，将助力新产品开发与市场扩容。
6. 疫苗价值认知度提升：随着公众与社区对健康管理愈发主动，加之各类宣传活动对免疫接种与疾病预防价值的普及，公众对卡介苗等疫苗的需求持续走高。
7. 部分地区结核病高发：结核病高流行地区始终存在稳定的卡介苗接种需求。结核病的流行态势，尤其是结核病流行高发国家，仍对卡介苗疫苗销售产生显著影响。
8. 医疗领域国际合作：各国政府、制药企业与国际组织为解决结核病等全球公共卫生难题所开展的协作，或将利好卡介苗疫苗市场。
9. 旅行与移民流动：人口在结核病患病率不同的区域间迁移，会对疫苗接种政策与实践产生影响，进而推高卡介苗疫苗的市场需求。
10. 全球大流行应急准备：新冠（COVID-19）疫情凸显了做好传染病防控准备的重要性。由此带来的对全球卫生安全关注度的提升，以及免疫规划相关投入的增加，或将为卡介苗疫苗市场带来发展机遇。